Highlights Oncopeptides AB

Equities

ONCO

SE0009414576

Market Closed - Nasdaq Stockholm Other stock markets 11:29:41 2024-05-02 am EDT			5-day change	1st Jan Change
2.915 ^SEK	+0.17%		-7.61%	-61.95%

Apr. 15	Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain	CI
Apr. 04	Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain	Apr. 15	CI
Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024	Apr. 04	CI
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	Mar. 27	CI
Oncopeptides AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Oncopeptides AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Global markets live: Domino's Pizza, Walt Disney, Broadcom, Ryanair, Exxon Mobil, Goldman Sachs...	Feb. 26
FDA Officially Withdraws Approval of Oncopeptides Pepaxto	Feb. 23	DJ
Oncopeptides to Assess US FDA's Withdrawal of Blood Cancer Drug Approval	Feb. 23	MT
Oncopeptides Receives Positive Recommendation for Pepaxti by Spanish Pricing Authority	Feb. 23	CI
Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines	Dec. 15	CI
Oncopeptides Selects to Present Additional Data from Ocean Study	Nov. 13	CI
Oncopeptides AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Oncopeptides AB Announces Its Decision to Adopt the Application Process to Allow Pertide Access to Patients with Relapsed, Refractory Multiple Myeloma	23-09-28	CI
Oncopeptides AB Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial Results	23-09-14	CI
Oncopeptides AB Publishes Two Articles with Results from Anchor and LIGHTHOUSE Studies in Haematologica	23-09-04	CI
Oncopeptides AB Announces Information Regarding the Formal Request from the U.S. Food and Drug Administration	23-08-25	CI
Oncopeptides AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Oncopeptides Hails Swedish Authority's Decision to End Probe into Chief Scientific Officer	23-05-30	MT
Oncopeptides Presents New Data at the European Haematology Association Meeting	23-05-11	CI
Oncopeptides AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oncopeptides AB

Equities

ONCO

SE0009414576

Highlights

Filters